ProSomnus (OSA) versus Its Peers Critical Survey

ProSomnus (NASDAQ:OSA) is one of 221 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it contrast to its rivals? We will compare ProSomnus to related businesses based on the strength of its institutional ownership, risk, profitability, dividends, earnings, analyst recommendations and valuation.

Earnings & Valuation

This table compares ProSomnus and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ProSomnus	$27.65 million	-$24.09 million	-0.10
ProSomnus Competitors	$915.00 million	$6.84 million	-5.61

ProSomnus’ rivals have higher revenue and earnings than ProSomnus. ProSomnus is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares ProSomnus and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProSomnus	-87.14%	N/A	-106.30%
ProSomnus Competitors	-772.65%	-154.89%	-30.47%

Volatility & Risk

ProSomnus has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. Comparatively, ProSomnus’ rivals have a beta of 1.44, indicating that their average share price is 44% more volatile than the S&P 500.

Institutional and Insider Ownership

70.0% of ProSomnus shares are owned by institutional investors. Comparatively, 47.3% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 7.7% of ProSomnus shares are owned by insiders. Comparatively, 15.7% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for ProSomnus and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProSomnus	0	1	2	0	2.67
ProSomnus Competitors	1451	3995	7824	193	2.50

ProSomnus presently has a consensus target price of $2.33, suggesting a potential upside of 1,455.56%. As a group, “Surgical & medical instruments” companies have a potential upside of 31.53%. Given ProSomnus’ stronger consensus rating and higher possible upside, research analysts plainly believe ProSomnus is more favorable than its rivals.

Summary

ProSomnus beats its rivals on 7 of the 13 factors compared.

About ProSomnus

ProSomnus, Inc. operates as a medical technology company that develops, manufactures, and markets precision intraoral medical devices for treating and managing patients with obstructive sleep apnea. The company sells its products to sleep dentists, sleep physicians, primary care providers, otolaryngologists, and other integrated healthcare service providers through a direct sales force. ProSomnus, Inc. is headquartered in Pleasanton, California.